A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy
Autor: | Alina Porfire, Alina Sesarman, Dana Muntean, Rareș Ionuț Știufiuc, Cristian Moldovan, Ioan Tomuță, Alin Moldovan, Cristina Barbălată, Valentin Florian Rauca, Manuela Banciu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Drug
liposomes Liposome Simvastatin Colorectal cancer Chemistry media_common.quotation_subject screening Pharmaceutical Science Pharmacology medicine.disease In vitro Quality by Design Article QbD RS1-441 Pharmacy and materia medica colon cancer Doxorubicin medicine Critical quality attributes medicine.drug media_common |
Zdroj: | Pharmaceutics Pharmaceutics, Vol 13, Iss 1526, p 1526 (2021) Volume 13 Issue 10 |
ISSN: | 1999-4923 |
Popis: | An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing the Quality by Design (QbD) concept, as a means to enhance the antiproliferative effect of the co-formulation on C26 murine colon cancer cells co-cultured with macrophages. It is known that the quality profile of liposomes is dependent on the critical quality attributes (CQAs) of liposomes (drug entrapped concentration, encapsulation efficiency, size, zeta potential, and drug release profile), which are, in turn, directly influenced by various formulation factors and processing parameters. By using the design of experiments, it was possible to outline the increased variability of CQAs in relation to formulation factors and identify by means of statistical analysis the material attributes that are critical (phospholipids, DOX and SIM concentration) for the quality of the co-formulation. The in vitro studies performed on a murine colon cancer cell line highlighted the importance of delivering the optimal drug ratio at the target site, since the balance antiproliferative vs. pro-proliferative effects can easily be shifted when the molar ratio between DOX and SIM changes. |
Databáze: | OpenAIRE |
Externí odkaz: |